Clinical Trial Update: Efficacy, Safety and Tolerability of CG428 Cutaneous Solution on Chemotherapy Induced Alopecia; Controlled Study (ELAN) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating CG428 Cutaneous Solution for efficacy, safety, and tolerability in chemotherapy-induced alopecia (ELAN) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alopecia

Drugs mentioned

• CG428 Cutaneous Solution

Snippet

Sponsor: Legacy Healthcare SA | Conditions: Alopecia | Phase 2 | Status: COMPLETED